Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Christos, Chouaid ^a   Hervé, Le C ^b   Chrystelle, Locher ^c   Cecile, Dujon ^d   Pascal, Thomas ^e   Jean Bernard, Auliac ^f   Isabelle, Monnet ^g   Alain, Vergnenegre ^h  

^a HÔPITAL SAINT ANTOINE   (France)

^b CH de Draguignan   (France)

^c CH de Meaux   (France)

^d CHI de Versailles   (France)

^e CH de Gap   (France)

^f CH de Mantes La Jolie ^*  (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^h LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Cost utility; Elderly patients; Erlotinib; Non small cell lung cancer; Phase II trial

Indexed keywords

DOCETAXEL; ERLOTINIB; ERYTHROPOIETIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CLINICAL STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; GERIATRICS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HEALTH STATUS; HOSPITALIZATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DISEASE PROGRESSION; FRANCE; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; QUINAZOLINES; TAXOIDS;

EID: 84868701036     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-301     Document Type: Article

References (23)

1. Yabroff KR Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 2011, 20:2006-2014. 10.1158/1055-9965.EPI-11-0650, 3191884, 21980008.
2. Chouaid C, Atsou K, Hejblum G, Vergnengre A. Economics of treatments for non-small cell lung cancer. PharmacoEconomics 2009, 27:113-125. 10.2165/00019053-200927020-00003, 19254045.
3. Pallis AG, Georgoulias V. Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? 2011, Lung Cancer: What has meta-analyses contributed to today's standard of care.
4. Jatoi A, Hillman S, Stella P, Green E, Adjei A, Nair S, Perez E, Amin B, Schild SE, Castillo R, Jett JR. North Central Cancer Treatment Group. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005, 23:9113-9119. 10.1200/JCO.2005.03.7465, 16361618.
5. Gridelli C, Maione P, Illiano A, Piantedosi FV, Favaretto A, Bearz A, Robbiati SF, Filipazzi V, Lorusso V, Carrozza F, Iaffaioli RV, Manzione L, Gallo C, Morabito A, Perrone F. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES 2P studies. J Clin Oncol 2007, 25:4663-4669. 10.1200/JCO.2007.12.5708, 17925563.
6. Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B. Intergroupe Francophone de Cancérologie Thoracique: Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011, 378:1079-1088. 10.1016/S0140-6736(11)60780-0, 21831418.
7. LeCaer H, Fournel P, Jullian H, Chouaid C, Letreut J, Thomas P, Paillotin D, Perol M, Gimenez C, Vergnenegre A. An open multicenter phase II trial of docetaxel -gemcitabine in Charlson score and performance status selected elderly patients with stage IIIB pleur /IV non-small-cell lung cancer: The GFPC 02-02a study. Crit Rev Oncol Hematol 2007, 64:73-81. 10.1016/j.critrevonc.2007.06.008, 17669664.
8. Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morère JF, Milleron B, Debieuvre D, Castéra D, Souquet PJ, Moro-Sibilot D, Lemarié E, Kessler R, Janicot H, Braun D, Spaeth D, Quantin X, Clary C. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005, 16:602-610. 10.1093/annonc/mdi126, 15741225.
9. Pallis AG, Gridelli C, van Meerbeeck JP, Greillier L, Wedding U, Lacombe D, Welch J, Belani CP, Aapro M. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology(SIOG): experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol 2010, 21:692-706. 10.1093/annonc/mdp360, 19717538.
10. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR 21. J Clin Oncol 2008, 26:2350-2357. 10.1200/JCO.2007.15.2280, 18467727.
11. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for non-small-cell-lung advanced cancer. J Clin Oncol 2007, 25:760-766. 10.1200/JCO.2006.07.5754, 17228019.
12. Lecaer H, Barlesi F, Corre R, Jullian H, Bota S, Falchero L, Vergnenegre A, Dujon C, Delhoume JY, Chouaid C. A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study). Br J Cancer 2011, 105:1123-1130. 10.1038/bjc.2011.331, 3208485, 21934690.
13. Ministère de la Santé et des Solidarités Arrêté du 27 février 2007 relatif à la classification et à la prise en charge des prestations d'hospitalisation pour les activités de médecine, chirurgie, obstétrique et odontologie et pris en application de l'article L. 162-22-6 du code de la sécurité sociale. Journal Officiel 2007, 50:28-72. Ministère de la Santé et des Solidarités.
14. Nomenclature Générale des Actes Professionnels Union des Caisses Nationales de Sécurité Sociale (UCANSS) http://www.ameli.fr/fileadmin/user_upload/documents/NGAP-oct-2009.pdf., Nomenclature Générale des Actes Professionnels.
15. Chouaid C, Molinier L, Combescure C, Daurès JP, Housset B, Vergnenègre A. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 2004, 90:397-402. 10.1038/sj.bjc.6601547, 2409571, 14735183.
16. Lewis G, Peake M, Aultman R, Gyldmark M, Morlotti L, Creeden J, de la Orden M. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res 2010, 38:9-21.
17. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health and Quality of Life Outcome 2008, 6. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579282/pdf/1477-7525-6-84.pdf..
18. Maniadakis N, Fragoulakis V, Pallis A, Prezerakos P, Georgoulias V. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece. Lung Cancer 2007, 58:275-81. 10.1016/j.lungcan.2007.06.012, 17688969.
19. Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB. NCIC Clinical Trials Group Working Group on Economic Analysis: Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 2010, 102:298-306. 10.1093/jnci/djp518, 20160168.
20. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008, 61:405-15. 10.1016/j.lungcan.2007.12.023, 18295368.
21. Cromwell I, van der Hoek K, Melosky B, Peacock S. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis. J Thorac Oncol 2011, 6:2097-103. 10.1097/JTO.0b013e31822f657a, 22052223.
22. Tabberer M, Stamuli E, Walker M. Utilities associated with non-small cell lung cancer (NSCLC): a community study. Value Health 2006, 9:A298.
23. Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. PharmacoEconomics 2001, 19:855-63. 10.2165/00019053-200119080-00007, 11596837.